{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:25:05Z","timestamp":1761567905069,"version":"build-2065373602"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.cpet.2022.03.009","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T19:19:29Z","timestamp":1655320769000},"page":"479-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings"],"prefix":"10.1016","volume":"17","author":[{"given":"Andrew B.","family":"Newberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Coble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2022.03.009_bib1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human Services task force on alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurol"},{"key":"10.1016\/j.cpet.2022.03.009_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1212\/WNL.38.3.359","article-title":"The NINCDS-ADRDA Workgroup criteria for the clinical diagnosis of probable Alzheimer's disease. A clinical pathological study of 57 cases","volume":"38","author":"Tierney","year":"1988","journal-title":"Neurol"},{"key":"10.1016\/j.cpet.2022.03.009_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ana.410240110","article-title":"Clinical diagnosed Alzheimer's disease. autopsy results in 150 cases","volume":"24","author":"Joachim","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cpet.2022.03.009_bib4","first-page":"325","article-title":"zheimer\u2019s disease facts and figures","volume":"13","year":"2017","journal-title":"Alzheimer\u2019s Dement"},{"issue":"3","key":"10.1016\/j.cpet.2022.03.009_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.cpet.2022.03.009_bib6","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/jnnp.2005.085332","article-title":"Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer\u2019s Disease","volume":"77","author":"Portet","year":"2006","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"4","key":"10.1016\/j.cpet.2022.03.009_bib7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2967\/jnumed.119.230797","article-title":"Predictive value of 18 F-florbetapir and 18 F-FDG PET for conversion from mild cognitive impairment to alzheimer dementia","volume":"61","author":"Blazhenets","year":"2020","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.cpet.2022.03.009_bib8","first-page":"13","article-title":"Positron emission tomography in the differential diagnosis of organic dementias","volume":"33","author":"Heiss","year":"1991","journal-title":"J\u00a0Neural Transm Suppl"},{"key":"10.1016\/j.cpet.2022.03.009_bib9","first-page":"S410","article-title":"The effect of disease severity on local cerebral glucose metabolism in Alzheimer's disease","volume":"7","author":"Jamieson","year":"1987","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.cpet.2022.03.009_bib10","first-page":"35","article-title":"High-resolution PET studies in Alzheimer's disease","volume":"4","author":"Kumar","year":"1991","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.cpet.2022.03.009_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00004424-199102000-00019","article-title":"Positron emission tomography in neuropsychiatry","volume":"26","author":"Faulstich","year":"1991","journal-title":"Invest Radiol"},{"key":"10.1016\/j.cpet.2022.03.009_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0001-2998(05)80238-7","article-title":"Single photon tomography in Alzheimer's disease and the dementias","volume":"20","author":"Bonte","year":"1990","journal-title":"Semin Nucl Med"},{"issue":"Suppl 1","key":"10.1016\/j.cpet.2022.03.009_bib13","first-page":"168","article-title":"Family history of dementia and regional cerebral glucose utilization (rCMRgle) in dementia of the Alzheimer type (AD) [Abstract]","volume":"39","author":"Friedland","year":"1989","journal-title":"Neurol"},{"key":"10.1016\/j.cpet.2022.03.009_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-1-4684-5931-9_18","article-title":"Abnormal brain glucose metabolism in Alzheimer's disease as measured by positron emission tomography","volume":"291","author":"Rapoport","year":"1991","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.cpet.2022.03.009_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.exger.2017.07.004","article-title":"A\u00a0cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease","volume":"107","author":"Croteau","year":"2018","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.cpet.2022.03.009_bib16","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00259-018-4039-7","article-title":"Clinical utility of FDG-PET for the clinical diagnosis in MCI","volume":"45","author":"Arbizu","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2022.03.009_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0001-2998(05)80118-7","article-title":"The use of positron emission tomography in the clinical assessment of dementia","volume":"22","author":"Mazziotta","year":"1992","journal-title":"Semin Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2022.03.009_bib18","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3233\/JAD-201094","article-title":"Effect of Alzheimer\u2019s disease and lewy body disease on metabolic chnages","volume":"79","author":"Lee","year":"2021","journal-title":"J\u00a0Alzheimer\u2019s Dis"},{"issue":"6","key":"10.1016\/j.cpet.2022.03.009_bib19","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1212\/WNL.50.6.1585","article-title":"Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease","volume":"50","author":"Ib\u00e1\u00f1ez","year":"1998","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.cpet.2022.03.009_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pscychresns.2006.12.003","article-title":"Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease","volume":"155","author":"Hunt","year":"2007","journal-title":"Psych Res Neuroimag"},{"issue":"6","key":"10.1016\/j.cpet.2022.03.009_bib21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1212\/WNL.38.6.909","article-title":"Longitudinal studies of regional cerebral metabolism in Alzheimer's disease","volume":"38","author":"Jagust","year":"1988","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.cpet.2022.03.009_bib22","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/archneur.1992.00530350056020","article-title":"Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease: pathophysiologic implications","volume":"49","author":"Smith","year":"1992","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.cpet.2022.03.009_bib23","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.159.5.738","article-title":"Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer\u2019s disease treatment studies","volume":"159","author":"Alexander","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.cpet.2022.03.009_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/brain\/118.1.185","article-title":"Chromosome 14 linked familial Alzheimer's disease: a clinico-pathological study of a single pedigree","volume":"118","author":"Kennedy","year":"1995","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.cpet.2022.03.009_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00003072-200307000-00006","article-title":"A\u00a0metabolic imaging severity rating scale for the assessment of cognitive impairment","volume":"28","author":"Newberg","year":"2003","journal-title":"Clin Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2022.03.009_bib26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/ene.13728","article-title":"European Association of Nuclear Medicine and the European Academy of Neurology recommendations for the use of brain 18F-flourodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: delphi Consensus","volume":"25","author":"Nobili","year":"2018","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.cpet.2022.03.009_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00002093-199601030-00005","article-title":"Positron emission tomography metabolic data corrected for cortical atrophy using magnetic resonance imaging","volume":"10","author":"Labb\u00e9","year":"1996","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"10","key":"10.1016\/j.cpet.2022.03.009_bib28","first-page":"1681","article-title":"Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators","volume":"34","author":"Alavi","year":"1993","journal-title":"J\u00a0Nucl Med"},{"issue":"7","key":"10.1016\/j.cpet.2022.03.009_bib29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","article-title":"Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI","volume":"32","author":"Landau","year":"2011","journal-title":"Neurobiol Aging"},{"issue":"5","key":"10.1016\/j.cpet.2022.03.009_bib30","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/brain\/awf097","article-title":"The neural substrates of episodic memory impairment in Alzheimer\u2019s disease as revealed by FDG\u2013PET: relationship to degree of deterioration","volume":"125","author":"Desgranges","year":"2002","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.cpet.2022.03.009_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrneurol.2009.217","article-title":"The use of PET in Alzheimer disease","volume":"6","author":"Nordberg","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.cpet.2022.03.009_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1749-6632.1993.tb23078.x","article-title":"Activation PET as an instrument to determine therapeutic efficacy in Alzheimer's disease","volume":"695","author":"Heiss","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.cpet.2022.03.009_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2005.06.003","article-title":"Ways toward an early diagnosis in Alzheimer\u2019s disease: the Alzheimer\u2019s disease neuroimaging initiative (ADNI)","volume":"1","author":"Mueller","year":"2005","journal-title":"Alz Demen"},{"issue":"6","key":"10.1016\/j.cpet.2022.03.009_bib34","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in\u00a0vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.cpet.2022.03.009_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mednuc.2016.12.002","article-title":"\u03b2-amyloid PET neuroimaging: a review of radiopharmaceutical development","volume":"41","author":"Dupont","year":"2017","journal-title":"M\u00e9decine Nucl\u00e9aire"},{"key":"10.1016\/j.cpet.2022.03.009_bib36","series-title":"PET imaging of dementia. InDiseases of the brain, head & neck, spine 2012\u20132015","first-page":"244","author":"Sabri","year":"2012"},{"key":"10.1016\/j.cpet.2022.03.009_bib37","doi-asserted-by":"crossref","first-page":"624330","DOI":"10.3389\/fnagi.2021.624330","article-title":"PET neuroimaging of Alzheimer\u2019s disease: radiotracers and their utility in clinical research","volume":"13","author":"Bao","year":"2021","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"10.1016\/j.cpet.2022.03.009_bib38","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.109.069088","article-title":"In\u00a0vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18)","volume":"51","author":"Wong","year":"2010","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2022.03.009_bib39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging \u03b2-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"J\u00a0Amer Med Assoc"},{"key":"10.1016\/j.cpet.2022.03.009_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.dadm.2017.06.001","article-title":"Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease","volume":"9","author":"Salloway","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.cpet.2022.03.009_bib41","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer\u2019s disease: implications for sequence of pathological events in Alzheimer\u2019s disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.cpet.2022.03.009_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13195-021-00807-6","article-title":"Early detection of amyloid load using 18F-florbetaben PET","volume":"13","author":"Bullich","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.cpet.2022.03.009_bib43","first-page":"5","article-title":"A\u00a0systematic review and meta-analysis of 18F-labeled amyloid imaging in Alzheimer's disease","volume":"1","author":"Yeo","year":"2015","journal-title":"Alz Demen"},{"issue":"4","key":"10.1016\/j.cpet.2022.03.009_bib44","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3233\/JAD-200990","article-title":"Amyloid hypothesis: the emperor's new clothes?","volume":"78","author":"H\u00f8ilund-Carlsen","year":"2020","journal-title":"J\u00a0Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.cpet.2022.03.009_bib45","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00259-015-3228-x","article-title":"Diagnostic accuracy of 18 F amyloid PET tracers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"43","author":"Morris","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2022.03.009_bib46","first-page":"63","article-title":"Cost-effectiveness of florbetapir-PET in alzheimer's disease: a Spanish Societal perspective","volume":"18","author":"Hornberger","year":"2015","journal-title":"J\u00a0Ment Health Policy Econ"},{"key":"10.1016\/j.cpet.2022.03.009_bib47","first-page":"CD012216","article-title":"18F PET with florbetapir for the early diagnosis of Alzheimer\u2019s disease dementia and other dementias in people with mild cognitive impairment (MCI)","volume":"11","author":"Mart\u00ednez","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.cpet.2022.03.009_bib48","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","article-title":"Frequent amyloid deposition without significant cognitive impairment among the elderly","volume":"65","author":"Aizenstein","year":"2008","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1016\/j.cpet.2022.03.009_bib49","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","article-title":"Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting","volume":"75","author":"Roberts","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cpet.2022.03.009_bib50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1155\/2009\/609839","article-title":"Amyloid imaging in aging and demen- tia: testing the amyloid hypothesis in\u00a0vivo","volume":"21","author":"Rabinovici","year":"2009","journal-title":"Behav Neurol"},{"issue":"2","key":"10.1016\/j.cpet.2022.03.009_bib51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00259-011-1960-4","article-title":"Amyloid-\u03b2 imaging with PET in Alzheimer\u2019s disease: is it feasible with current radiotracers and technologies?","volume":"39","author":"Moghbel","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.cpet.2022.03.009_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejrad.2017.07.014","article-title":"The diagnostic value of FDG and amyloid PET in Alzheimer\u2019s disease\u2014a systematic review","volume":"94","author":"Rice","year":"2017","journal-title":"Eur J Radiol"},{"issue":"25","key":"10.1016\/j.cpet.2022.03.009_bib53","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMoa054625","article-title":"PET of brain amyloid and tau in mild cognitive impairment","volume":"355","author":"Small","year":"2006","journal-title":"N\u00a0Eng J Med"},{"issue":"6","key":"10.1016\/j.cpet.2022.03.009_bib54","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00259-015-3231-2","article-title":"Tau imaging in neurodegenerative diseases","volume":"43","author":"Dani","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.cpet.2022.03.009_bib55","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11910-014-0500-6","article-title":"Tau PET imaging in Alzheimer\u2019s disease","volume":"14","author":"Okamura","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.cpet.2022.03.009_bib56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3233\/JAD-122059","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807","volume":"34","author":"Chien","year":"2013","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.cpet.2022.03.009_bib57","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/brain\/awu064","article-title":"Non-invasive assessment of Alzheimer\u2019s disease neurofibrillary pathology using 18F-THK5105 PET","volume":"137","author":"Okamura","year":"2014","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.cpet.2022.03.009_bib58","doi-asserted-by":"crossref","first-page":"e0226265","DOI":"10.1371\/journal.pone.0226265","article-title":"Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer\u2019s disease differ according to disease severity and amyloid positivity","volume":"14","author":"Park","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cpet.2022.03.009_bib59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H","article-title":"Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex","volume":"48","author":"Kuhl","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cpet.2022.03.009_bib60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13195-020-00749-5","article-title":"Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment","volume":"13","author":"Pyun","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.cpet.2022.03.009_bib61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JAD-2010-101290","article-title":"Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients","volume":"24","author":"Keller","year":"2011","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.cpet.2022.03.009_bib62","first-page":"85","article-title":"PET and fMRI to evaluate the results of acupuncture treatment of the cognition of alzheimer's disease","volume":"2","author":"Xu","year":"2004","journal-title":"Chin Imaging J Int Trad West Med"},{"issue":"1","key":"10.1016\/j.cpet.2022.03.009_bib63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/sj.clpt.6100232","article-title":"A\u00a0positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease","volume":"83","author":"Raje","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cpet.2022.03.009_bib64","first-page":"192","article-title":"A\u00a0randomized, double-blind, phase 2 study of the effects of the vaccine Vanutide cridificar with QS-21 adjuvant on immunogenicity, Safety and amyloid imaging in patients with mild to moderate alzheimer's disease","volume":"3","author":"Ketter","year":"2016","journal-title":"J\u00a0Prev Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.cpet.2022.03.009_bib65","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"10004","key":"10.1016\/j.cpet.2022.03.009_bib66","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","article-title":"Frontotemporal dementia","volume":"386","author":"Bang","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cpet.2022.03.009_bib67","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/ana.20873","article-title":"Frontotemporal dementia: clinicopathological correlations","volume":"59","author":"Forman","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cpet.2022.03.009_bib68","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.neurobiolaging.2003.10.007","article-title":"Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia, a PET study","volume":"25","author":"Diehl","year":"2004","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.cpet.2022.03.009_bib69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000077732","article-title":"Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: a prospective 18F-FDG-PET study","volume":"18","author":"Grimmer","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"2","key":"10.1016\/j.cpet.2022.03.009_bib70","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1212\/WNL.0000000000009760","article-title":"Longitudinal structural and metabolic changes in frontotemporal dementia","volume":"95","author":"Bejanin","year":"2020","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.cpet.2022.03.009_bib71","first-page":"1875","article-title":"Cerebral glucose metabolism in patients with frontotemporal dementia","volume":"39","author":"Ishii","year":"1998","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2022.03.009_bib72","doi-asserted-by":"crossref","first-page":"e0141672","DOI":"10.1371\/journal.pone.0141672","article-title":"Right limbic FDG-PET hypometabolism correlates with emotion recognition and attribution in probable behavioral variant of frontotemporal dementia patients","volume":"10","author":"Cerami","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cpet.2022.03.009_bib73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13195-019-0470-7","article-title":"18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes","volume":"11","author":"Tsai","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.cpet.2022.03.009_bib74","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ana.20332","article-title":"In\u00a0vivo detection of microglial activation in frontotemporal dementia","volume":"56","author":"Cagnin","year":"2004","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.cpet.2022.03.009_bib75","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/nan.12092","article-title":"Patterns of microglial cell activation in frontotemporal lobar degeneration","volume":"40","author":"Lant","year":"2014","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5\u20138","key":"10.1016\/j.cpet.2022.03.009_bib76","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13195-014-0052-7","article-title":"Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11 C altropane positron emission tomography study","volume":"6","author":"Marquie","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.cpet.2022.03.009_bib77","doi-asserted-by":"crossref","first-page":"fcaa040","DOI":"10.1093\/braincomms\/fcaa040","article-title":"18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies","volume":"2","author":"Graff-Radford","year":"2020","journal-title":"Brain Commun"},{"issue":"3","key":"10.1016\/j.cpet.2022.03.009_bib78","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1212\/WNL.0000000000008818","article-title":"\u03b2-amyloid PET and neuropathology in dementia with Lewy bodies","volume":"94","author":"Kantarci","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.cpet.2022.03.009_bib79","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","article-title":"The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies","volume":"50","author":"Lim","year":"2009","journal-title":"J\u00a0Nucl Med"},{"issue":"4","key":"10.1016\/j.cpet.2022.03.009_bib80","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1212\/WNL.0b013e3181ab2b58","article-title":"Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET","volume":"73","author":"Shimada","year":"2009","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.cpet.2022.03.009_bib81","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1093\/brain\/awm177","article-title":"FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease","volume":"130","author":"Foster","year":"2007","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.cpet.2022.03.009_bib82","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","article-title":"Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic Cohort: the ABIDE project","volume":"75","author":"de Wilde","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.cpet.2022.03.009_bib83","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2019.10.020","article-title":"Distinguishing between dementia with Lewy bodies and Alzheimer's disease using metabolic patterns","volume":"87","author":"Ye","year":"2020","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.cpet.2022.03.009_bib84","doi-asserted-by":"crossref","first-page":"102754","DOI":"10.1016\/j.nicl.2021.102754","article-title":"FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD","volume":"31","author":"Kantarci","year":"2021","journal-title":"Neuroimage Clin"},{"issue":"3","key":"10.1016\/j.cpet.2022.03.009_bib85","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1097\/RLU.0b013e318279b991","article-title":"Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia","volume":"38","author":"Garibotto","year":"2013","journal-title":"Clin Nucl Med"},{"issue":"11","key":"10.1016\/j.cpet.2022.03.009_bib86","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1212\/WNL.0b013e3181d55f61","article-title":"Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in\u00a0vivo","volume":"74","author":"Klein","year":"2010","journal-title":"Neurology"},{"issue":"Pt 6","key":"10.1016\/j.cpet.2022.03.009_bib87","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/brain\/awr089","article-title":"Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography","volume":"134","author":"Burke","year":"2011","journal-title":"Brain"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859822000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859822000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:11:19Z","timestamp":1761563479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859822000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1556859822000244"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2022.03.009","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2022.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}